IM Cannabis Closes $1.31M Offering; Director-Linked Firm Takes 25% of Shares
IMCC sits 85% above its 52-week low of $1.55 on light trading volume (0.2× avg).
Summary
IM Cannabis closed its US$1.31 million registered direct offering at US$2.00 per share, with a director-linked company taking roughly 25% of the shares under a financial hardship exemption.
Key Events · Financing and Capital Events · IMCC
-
Offering Closed at US$2.00
655,000 common shares sold at US$2.00 each for gross proceeds of US$1.31 million, before offering expenses.
-
Related Party Took 25%
Invest-Pro, a company where director Eli Zamir is also a director, subscribed for 164,585 shares for US$329,170 — roughly 25% of the offering.
-
Financial Hardship Exemption
The board relied on MI 61-101 sections 5.5(g) and 5.7(1)(e), determining the Company was in serious financial difficulty and the offering was designed to improve its financial position.
-
Proceeds for Working Capital
Net proceeds are intended for working capital and general corporate purposes, including evaluating potential additional business opportunities.
Analysis · IMCC · Life Sciences
The offering closed on the terms priced yesterday, but the new disclosure is the related party participation: Invest-Pro, a company where director Eli Zamir is also a director, subscribed for 164,585 shares — roughly 25% of the 655,000-share offering — for US$329,170. The board relied on a financial hardship exemption under MI 61-101, explicitly determining the Company was in serious financial difficulty. That formal hardship finding, combined with the going concern and Nasdaq delisting risk already disclosed in August, underscores how acute the liquidity pressure is. The capital is real and needed, but the terms and the insider-linked participation show the Company had few alternatives.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.9% of the 1661 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMCC was trading at $2.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8M. The 52-week trading range was $1.55 to $77.10. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.